Several studies have shown that PPARα activation mediated by the PPARα agonist Feno promotes the expression of genes involved in hepatic β-FAO (Zhao et al., 2017)and limits hepatic steatosis associated with high-fat diet, T2DM and obesity-related insulin resistance (Kostapanos et al., 2013), nonalcoholic hepatitis (Kersten and Stienstra, 2017) and cholestatic liver disease (Ghonem et al., 2015). Here, PPARA is linked to fatty liver disease.